# Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease

> **NCT05335278** · NA · TERMINATED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 11 (actual)

## Conditions studied

- Interstitial Lung Disease
- Myopathy, Inflammatory

## Interventions

- **DRUG:** Nintedanib 150 milligrams [Ofev]

## Key facts

- **NCT ID:** NCT05335278
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-04-30
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05335278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05335278, "Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05335278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*